What Is Hindsight Bias In Investing?
You’ve probably heard the expression “hindsight is 20/20.” That saying…
Sell
37
MRNA Quote, Financials, Valuation and Earnings
Last price:
$31.35
Seasonality move
:
17.67%
Day range:
$33.51 - $34.86
52-week range:
$29.25 - $170.47
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.11x
P/B ratio:
1.20x
Volume:
6.9M
Avg. volume:
11M
1-year change:
-69.33%
Market cap:
$13.1B
Revenue:
$3.2B
EPS (TTM):
-$9.28
Analysts' Opinion
-
Consensus RatingModerna has received a consensus rating of Hold. The company's average rating is a Hold based on 5 Buy ratings, 17 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $53.44, Moderna has an estimated upside of 57.87% from its current price of $33.85.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing 100% downside risk from its current price of $33.85.
Fair Value
-
According to the consensus of 23 analysts, Moderna has 57.87% upside to fair value with a price target of $53.44 per share.
MRNA vs. S&P 500
-
Over the past 5 trading days, Moderna has underperformed the S&P 500 by -1.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Moderna does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Moderna revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Moderna reported revenues of $956M.
Earnings Growth
-
Moderna earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Moderna reported earnings per share of -$2.91.
Enterprise value:
6.1B
EV / Invested capital:
0.56x
Price / LTM sales:
4.11x
EV / EBIT:
--
EV / Revenue:
1.90x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.50x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$1.7B
Return On Assets:
-22.04%
Net Income Margin (TTM):
-111.32%
Return On Equity:
-29.09%
Return On Invested Capital:
-29.09%
Operating Margin:
-130.34%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $18.9B | $6.8B | $3.2B | $2.8B | $956M | |
| Gross Profit | $13.5B | $2.1B | $1.7B | $1.9B | $217M | |
| Operating Income | $9.4B | -$4.2B | -$3.9B | $6M | -$1.2B | |
| EBITDA | $9.8B | -$3.3B | -$3.4B | $278M | -$1.1B | |
| Diluted EPS | $19.96 | -$12.41 | -$9.28 | $0.55 | -$2.91 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $6.3B | $16.1B | $13.4B | $10.3B | $8.1B | |
| Total Assets | $7.3B | $24.7B | $25.9B | $18.4B | $14.1B | |
| Current Liabilities | $4.4B | $9.1B | $4.9B | $3B | $2.2B | |
| Total Liabilities | $4.8B | $10.5B | $6.7B | $4.6B | $3.2B | |
| Total Equity | $2.6B | $14.1B | $19.1B | $13.9B | $10.9B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5B | -$3.1B | -$3B | $622M | $825M | |
| Cash From Investing | -$5.2B | $4.2B | $1.9B | -$538M | -$539M | |
| Cash From Financing | -$3.4B | -$1.4B | $56M | -$109M | -$3M | |
| Free Cash Flow | $4.6B | -$3.8B | -$4.1B | $402M | $303M | |
MRNA
Sector
Market Cap
$13.1B
$39.2M
Price % of 52-Week High
19.86%
45.99%
Dividend Yield
0%
0%
Shareholder Yield
-0.41%
-0.81%
1-Year Price Total Return
-69.33%
-38.63%
Beta (5-Year)
1.863
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$33.70
200-day SMA
Sell
Level
$67.38
Bollinger Bands (100)
Sell
Level
33.32 - 45.9
Chaikin Money Flow
Buy
Level
448.3M
20-day SMA
Buy
Level
$33.37
Relative Strength Index (RSI14)
Sell
Level
48.93
ADX Line
Buy
Level
15.78
Williams %R
Neutral
Level
-64.697
50-day SMA
Sell
Level
$35.24
MACD (12, 26)
Sell
Level
-0.41
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
474.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.8559)
Buy
CA Score
(Annual)
Level (-0.1863)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.004)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Stock Forecast FAQ
In the current month, MRNA has received 5 Buy ratings 17 Hold ratings, and 1 Sell ratings. The MRNA average analyst price target in the past 3 months is $53.44.
-
Where Will Moderna Stock Be In 1 Year?
According to analysts, the consensus estimate is that Moderna share price will rise to $53.44 per share over the next 12 months.
-
What Do Analysts Say About Moderna?
Analysts are divided on their view about Moderna share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Moderna is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Moderna's Price Target?
The price target for Moderna over the next 1-year time period is forecast to be $53.44 according to 23 Wall Street analysts, 5 of them rate the stock a Buy, 1 rates the stock a Sell, and 17 analysts rate the stock a Hold.
-
Is MRNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Moderna is a Hold. 17 of 23 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of MRNA?
You can purchase shares of Moderna via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Moderna shares.
-
What Is The Moderna Share Price Today?
Moderna was last trading at $31.35 per share. This represents the most recent stock quote for Moderna. Yesterday, Moderna closed at $33.85 per share.
-
How To Buy Moderna Stock Online?
In order to purchase Moderna stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Stock Ideas
Buy
58
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
29
UNF alert for Mar 26
UniFirst [UNF] is up 0.93% over the past day.
Sell
30
KEQU alert for Mar 26
Kewaunee Scientific [KEQU] is down 4.43% over the past day.
Buy
82
EPAC alert for Mar 26
Enerpac Tool Group [EPAC] is down 2.45% over the past day.
